An Overview of Physical Stability of Pharmaceuticals

  • Yushen GuoEmail author
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XII)


From drug discovery and development to regulatory approval and marketing, the acceptable stability of the drug substance and drug product is one of the basic quality requirements. The overall stability of a drug product is related not only to the intrinsic chemical stability of the drug molecule, but also the physical form, manufacturing process, interactions among formulation components, package, and storage condition. In this paper, the major physical stability attributes of pharmaceuticals are discussed.


Dosage Form Drug Product Cocoa Butter Drug Substance Physical Stability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adesunloye TA, Stach PE (1998) Effect of glycine/citric acid on the dissolution stability of hard gelatin capsules. Drug Dev Ind Pharm 24:493–500CrossRefPubMedGoogle Scholar
  2. Almeida IF, Bahia MF (2006) Evaluation of the physical stability of two oleogels. Int J Pharm 327:73–77CrossRefPubMedGoogle Scholar
  3. Davis RE, Lorimer KA, Wilkowski MA, Rivers JH (2004) Studies of phase relationships in cocrystal systems. ACA Trans 39:41–61Google Scholar
  4. Digenis GA, Gold TB, Shah VP (1994) Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci 83:915–921CrossRefPubMedGoogle Scholar
  5. Guo Y (2008) Impact of solid-state characteristics to the physical stability of drug substance and drug product in handbook of stability testing in pharmaceutical development (Kim Huynh-Ba ed.), Springer, New York, NYGoogle Scholar
  6. Hlinak AJ, Kuriyan K, Morris KR, Reklaitis GV, Basu PK (2006) Understanding critical material properties for solid dosage form design. J Pharm Innovation 1(1):12–17CrossRefGoogle Scholar
  7. ICH guidance Q1A (R2) (2003) Stability testing of new drug substances and products
  8. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG (2001) Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48:91–114CrossRefPubMedGoogle Scholar
  9. Nakamura K, Yokohama S, Sonobe T (2002) Failure of stability prediction for minodronic acid injectable by accelerated stability testing. Int J Pharm 241:65–71CrossRefPubMedGoogle Scholar
  10. Rubino JT, Chen LL, Walker JT, Segretario J, Everlof JG, Hussain MA (1999) Photoinduced particulate matter in a parenteral formulation for bisnafide, an experimental antitumor agent. Pharm Dev Tech 4:439–447CrossRefGoogle Scholar
  11. Tong WQ, Clark J, Franklin ML, Jozwiakowski JP, Lemmo JB, Sisco JM, Whight SR (1996) Identification and characterization of the sulfate precipitate in GI147211C IV formulation. PDA J Pharm Sci and Tech 5:326–329Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.Achaogen Inc.South San FranciscoUSA

Personalised recommendations